For results that have...

But don't include...

Abstract

Click to add/remove this article to your list of 'My Favorites' Effect of D-chiro-inositol on Glucose Metabolism

Abstract Number: 2281-PO

Authors: JAE MIN LEE, HYUN JIN KIM, YOUNG SUK JO, BYUNG JUN KIM, SEONG-KYU LEE, BON JEONG KU, YOUNG KUN KIM, KANG SEO PARK, Daejeon, Republic of Korea

Results: Metabolic syndrome is a cluster of cardiovascular risk factors and it is closely related with insulin resistance. So, improvement of insulin resistance is important target of the treatment of metabolic syndrome and diabetes. D-chiro-inositol (DCI) is a phospholipid mediating intracellular insulin action. Recently, we reported that DCI had the glucose-lowering effect through the improvement insulin resistance in clinical study. To investigate the mechanism of the glucose-lowering effect of DCI, we explored the effect on glucose uptake, gene expression of adipocytokines and AMPK pathway in 3T3-L1 cells. 2-deoxyglucose uptake increased in DCI-treated cells by about 1.2-fold (relative to the control) and was inhibited by phosphoinositide 3-kinase (PI3kinase) inhibitors (Wortmanin, LY294002) and AMPK inhibitor (STO-609). In Western blot analysis, DCI did not show the difference of phosphorylation of Akt and AMPK compared with control. However, it decreased the gene expression of leptin and resistin in 3T3-L1 cells in a dose-dependent manner. These results suggest that DCI may involve other pathway of glucose metabolism, but not PI3 Kinase and AMPK signaling pathways and it may be useful in management of metabolic syndrome by improving insulin resistance through increasing glucose uptake and decreasing adipocytokines related with insulin resistance.[figure1][figure2][figure3]